U.S. Capital Markets Stock News

NasdaqGM:ATAI
NasdaqGM:ATAIPharmaceuticals

A Look At AtaiBeckley (ATAI) Valuation After Virtual Investor Day Announcement And Strong Recent Returns

AtaiBeckley (ATAI) is back on investor radars after announcing a March 6 Virtual Investor Day, where management plans to update the market on its mental health pipeline and broader development priorities. See our latest analysis for AtaiBeckley. That announcement comes after a solid run in the shares, with a 7 day share price return of 9.87% and a 90 day share price return of 15.73%, alongside a very strong 1 year total shareholder return of 150.87%. This suggests momentum has been building...
NYSE:WHD
NYSE:WHDEnergy Services

Softer Results and SPC Deal Might Change The Case For Investing In Cactus (WHD)

Cactus, Inc. has reported fourth-quarter 2025 revenue of US$261.2 million and net income of US$39.84 million, with full-year 2025 revenue of US$1.08 billion and net income of US$166.01 million, all modestly lower than the prior year. Despite the softer results, the recent acquisition of Baker Hughes’ Surface Pressure Control business and continued analyst interest suggest investors are closely watching how Cactus leverages its expanded international footprint. Next, we’ll explore how the...
NYSE:TDG
NYSE:TDGAerospace & Defense

TransDigm Margin Strain Tests Acquisition Model And Analyst Growth Expectations

TransDigm Group (NYSE:TDG) is seeing pressure on profit margins as higher interest expenses and raw material costs follow recent acquisitions. The company is still reporting revenue growth but now guides adjusted profit per share below market expectations. Analysts remain broadly supportive of the stock while highlighting that higher financing and input costs are important risks for profitability. TransDigm Group is a major supplier of highly engineered aerospace components, with exposure...
NasdaqGS:CLNE
NasdaqGS:CLNEOil and Gas

Clean Energy Fuels (CLNE) Loss Deepens To US$0.20 EPS Challenging Turnaround Narratives

Clean Energy Fuels (CLNE) has wrapped up FY 2025 with Q4 revenue of US$112.3 million and a basic EPS loss of US$0.20, while the trailing twelve months show revenue of US$424.8 million and a basic EPS loss of US$1.01, keeping the story firmly in loss-making territory. Over recent quarters the company has seen quarterly revenue move in a tight band between US$102.6 million and US$112.3 million, as quarterly basic EPS losses ranged from US$0.09 to US$0.60. This has left investors focused on how...
NYSE:CL
NYSE:CLHousehold Products

Is Colgate Palmolive (CL) Still Reasonably Priced After Its Strong Recent Share Performance

If you are wondering whether Colgate-Palmolive at around US$96.67 is still a sensible entry or hold, the key question is how that price stacks up against the company’s underlying value. The stock has recently delivered returns of 1.1% over 7 days, 13.5% over 30 days, 24.4% year to date, 9.9% over 1 year, 43.1% over 3 years and 45.8% over 5 years, which naturally raises questions about how much of the story is already reflected in the share price. Recent news flow around Colgate-Palmolive has...
NYSE:CNR
NYSE:CNROil and Gas

Does Core Natural Resources (CNR) Price Reflect Its Recent Weakness And Strong DCF Upside Potential

If you are wondering whether Core Natural Resources is still offering good value after its run in recent years, this article will walk through what the current share price might be implying. The stock recently closed at US$86.84, with a 2.4% decline over 7 days, a 9.2% decline over 30 days and a 3.4% decline year to date, while the 1 year return stands at 16.0%, the 3 year return at 53.7% and the 5 year return is roughly 7x. Recent coverage has focused on Core Natural Resources' position in...
NYSE:MPT
NYSE:MPTHealth Care REITs

Evaluating Medical Properties Trust (MPT) After Profit Return And Dividend Hike

Why Medical Properties Trust is back on investors’ radar Medical Properties Trust (MPT) has drawn fresh attention after returning to quarterly profitability, lifting its dividend and working through tenant bankruptcies and high leverage via property sales and new leases. See our latest analysis for Medical Properties Trust. The recent fourth quarter earnings return to profit, dividend increase and progress on tenant issues have coincided with a 13.83% 1 month share price return and a 13.39%...
NYSE:MDT
NYSE:MDTMedical Equipment

Medtronic (MDT) Valuation Check As MiniMed IPO And Stealth AXiS Approval Reshape The Business

Medtronic (MDT) is reshaping its business with plans to spin off its Diabetes segment through a MiniMed Group IPO, while advancing its Stealth AXiS spine surgery platform, moves that directly affect how investors may view the stock. See our latest analysis for Medtronic. Despite a recent soft patch, with a 30 day share price return of 3.99% decline and a 90 day share price return of 7.97% decline, Medtronic’s 1 year total shareholder return of 10.07% and 3 year total shareholder return of...
NYSE:CRK
NYSE:CRKOil and Gas

Dallas Salazar’s New Family Office Renews Focus On Comstock Resources

Early Comstock Resources investor Dallas C. Salazar has launched a new family office, Two Texas Presidents, focused on energy sector investments. Salazar has been involved in prior acquisition events at Comstock Resources, which brought him significant gains. The new family office keeps attention on Comstock Resources' history with high profile energy investors such as Salazar. For investors watching Comstock Resources (NYSE:CRK), the launch of Two Texas Presidents adds context around the...
NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

Strategy (MSTR) Deepens Bitcoin-For-Equity Bet: Smart Treasury Innovation or Mounting Balance-Sheet Risk?

Strategy Inc., formerly MicroStrategy, recently completed its 100th Bitcoin purchase, adding 592 BTC for about US$39.8 million and funding the acquisition by selling roughly 297,940 common shares, reinforcing Bitcoin as its primary treasury reserve asset. This milestone underlines Strategy’s singular commitment to an aggressive Bitcoin accumulation model at a time when most corporate treasuries have stepped back, intensifying debate over balance-sheet risk and shareholder dilution. Next, we...
NYSE:AGX
NYSE:AGXConstruction

Argan (AGX) Valuation Check After New Texas AI Power Plant Contracts

Argan (AGX) has drawn fresh attention after announcing two large Texas contracts to build power plants that will supply electricity to data centers running AI workloads, directly connecting its project pipeline to AI driven power demand. See our latest analysis for Argan. The latest Texas wins sit against a sharp share price run, with Argan’s 30 day share price return of 25.13% and year to date share price return of 35.70% combining with a very large 1 year total shareholder return that...
NYSE:TFC
NYSE:TFCBanks

Truist Bitcoin ETFs And Open Banking Move Tie Into Undervalued Shares

Truist Financial (NYSE:TFC) is offering clients access to SEC registered spot Bitcoin ETFs through Truist Investment Services Inc. The bank has also launched open banking connectivity in partnership with Mastercard, giving clients new ways to link and manage financial data. These moves expand Truist Wealth's product shelf and introduce new digital tools for clients who want broader choice and more control. For a large US regional bank focused on retail, wealth, and commercial banking, this...
NYSE:VOYA
NYSE:VOYADiversified Financial

Is Voya (VOYA) Using F&G’s Annuities Partnership To Quietly Redefine Its Retirement Platform Strategy?

Earlier this week, F&G Annuities & Life, Inc. and Voya Financial, Inc. announced that F&G's annuity solutions will be distributed through Voya's Wealth Management platform, giving Voya financial professionals access to a broader suite of retirement and income protection products supported by education and product expertise. This collaboration highlights how Voya is using third-party partnerships to deepen its retirement offering without building every annuity product in-house, potentially...
NasdaqGS:MMYT
NasdaqGS:MMYTHospitality

A Look At MakeMyTrip (NasdaqGS:MMYT) Valuation After Q3 Growth, Buyback Expansion And OpenAI Collaboration

MakeMyTrip (MMYT) has drawn fresh attention after reporting strong third quarter leisure demand, higher accommodation volumes and a larger buyback authorization, alongside a new AI-led travel planning collaboration with OpenAI. See our latest analysis for MakeMyTrip. At a share price of $56.97, MakeMyTrip has faced a 10.64% 1 month share price return decline and a 30.43% year to date slide. However, its 3 year total shareholder return of 116.70% points to much stronger longer term momentum...
NYSE:LEU
NYSE:LEUOil and Gas

A Look At Centrus Energy's Valuation As Exclusive US HALEU Role And Expansion Plans Draw Attention

Centrus Energy (LEU) is back in focus after a series of announcements regarding its role as the only U.S. Nuclear Regulatory Commission licensed producer of high assay low enriched uranium, as well as a multibillion dollar capacity expansion. See our latest analysis for Centrus Energy. Those announcements and contracts have landed during a volatile stretch, with the share price at US$210.63 after a 1-day share price return of 1.67% and a 30-day share price return decline of 25.23%. The 1-year...
NasdaqGM:MNKD
NasdaqGM:MNKDBiotechs

United Therapeutics Rival Inhaler Tests MannKind Valuation And Royalty Outlook

United Therapeutics has introduced a new soft mist inhaler that is positioned as a direct competitor to MannKind's Tyvaso DPI. The new device is described as offering reduced side effects, including less coughing, compared with dry powder inhalers. This development raises questions about the durability of MannKind's royalty stream from Tyvaso DPI and could influence investor expectations for NasdaqGM:MNKD. MannKind, trading on NasdaqGM:MNKD, is closely tied to royalties from Tyvaso DPI, so...
NasdaqGM:MDB
NasdaqGM:MDBIT

Is MongoDB (MDB) Still Reasonably Priced After Recent Share Price Pullback

If you are wondering whether MongoDB's current share price still makes sense, you are not alone. This article will focus on what that price could mean for value focused investors. The stock last closed at US$314.99, with returns of a 13.2% decline over 7 days, a 23.4% decline over 30 days, a 21.2% decline year to date, a 17.4% gain over 1 year, 50.0% over 3 years, and a 10.5% decline over 5 years, which hints at changing expectations and risk perceptions over different timeframes. Recent...
NasdaqGS:NTAP
NasdaqGS:NTAPTech

A Look At NetApp (NTAP) Valuation As Earnings Approach And AI Storage Growth Draws Focus

NetApp (NTAP) heads into its upcoming earnings release with investor attention focused on two fronts: recent sector driven valuation resets and the company’s push into AI infrastructure, Keystone storage services, and public cloud offerings. See our latest analysis for NetApp. The recent 1 day share price return of 2.01% to US$101.88 comes after weeks of mixed signals, with a 30 day share price return of 3.11% but a 90 day decline of 6.75%. The 1 year total shareholder return of 16.47%...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Why Is Critical Metals (CRML) Balancing Insider Share Sales With Stronger Tanbreez Rare Earth Assays?

In February 2026, Critical Metals Corp. filed a US$25.17 million shelf registration for 2,777,600 ordinary shares, while also reporting its strongest rare earth element assay results to date from the Hill Deposit at the Tanbreez Heavy REE Project. The combination of insider plans to sell a large block of shares and encouraging heavy rare earth grades creates an unusual mix of financing and project-quality signals for investors to weigh. We’ll now examine how the strong Tanbreez assay...
NYSE:ANET
NYSE:ANETCommunications

Assessing Arista Networks (ANET) Valuation After AI Growth Guidance And Tech Rebound

Why Arista Networks Stock Is Back in Focus Arista Networks (ANET) is back on many investors’ screens after tech stocks rebounded on easing tariff worries, fresh AI infrastructure news, and management’s recently raised guidance tied to AI driven revenue expectations. See our latest analysis for Arista Networks. At a share price of US$132.89, Arista has seen a 3.2% one day share price return but a 7.5% 30 day share price decline. Its 1 year total shareholder return of 37.9% and very large 5...
NYSE:DCO
NYSE:DCOAerospace & Defense

Assessing Ducommun (DCO) Valuation As Q4 Earnings And Bullish Sentiment Draw Investor Attention

Why Ducommun’s upcoming Q4 report matters today Ducommun (DCO) is in focus today as it reports Q4 2025 results before the market opens, with investors watching how expected 10.3% year on year revenue growth compares with last quarter’s 5.5% increase. See our latest analysis for Ducommun. The share price has gained 13.9% over the past month and 38.3% over the last 90 days, while the 1 year total shareholder return of 120.8% points to strong momentum ahead of today’s $126.77 print and the...
NYSE:PFSI
NYSE:PFSIDiversified Financial

A Look At PennyMac Financial Services (PFSI) Valuation As Sales And Earnings Declines Draw Fresh Scrutiny

Why recent commentary on PennyMac Financial Services (PFSI) is drawing investor attention Recent commentary flagging a 10.4% annual sales decline and falling earnings per share over the past five years at PennyMac Financial Services (PFSI) has put the mortgage specialist’s fundamentals back in the spotlight. See our latest analysis for PennyMac Financial Services. At a share price of US$92.74, PennyMac Financial Services has seen a 1 day share price return of 1.69%. However, the 30 day share...
NYSE:DAN
NYSE:DANAuto Components

A Look At Dana (DAN) Valuation After CEO Transition To Byron Foster

Dana (DAN) is preparing for a leadership handover after naming Byron Foster as its next CEO and President, with current CEO R. Bruce McDonald set to remain Chairman to support a structured transition. See our latest analysis for Dana. The leadership news comes on top of a period of strong momentum, with a 30-day share price return of 17.16% and a 90-day share price return of 59.16%, while the 1-year total shareholder return of 135.16% points to a very strong multiyear outcome. If this...
NasdaqCM:SLNO
NasdaqCM:SLNOBiotechs

A Look At Soleno Therapeutics (SLNO) Valuation After Its Shift To Profitability And Earnings Beat

Soleno Therapeutics (SLNO) is in focus after reporting Q4 and full year 2025 results that moved from prior net losses to net income, with earnings per share also turning positive and topping analyst expectations. See our latest analysis for Soleno Therapeutics. The earnings surprise and shift to profitability come after a mixed period for the stock, with a 1 day share price return of 4.72% and 7 day share price return of 6.22% contrasting with a 90 day share price return decline of 17.24%,...